

***The company has released voluntary disclosures since 2015 in accordance with the EFPIA Code of Practice***

## **Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2024**

- In line with its commitment to transparency, Grifols has disclosed for the 10th consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA's (European Federation of Pharmaceutical Industries and Associations) scope, including Spain.
- In 2024, Grifols made transfers of value in Europe amounting to Euro 17.3 million. This represents a decrease of 19% compared to 2023. Of the total, 61% were transfers of value related to R&D, amounting to Euro 10.6 million.
- Transfers of value in Spain increased by 15% to Euro 8.1 million, although Spain generated 47% of the group's total transfers in Europe in 2024 and 64% of those related to R&D.
- In 2024, Grifols made transfers of value to 249 healthcare professionals in Spain that amounted to Euro 432,628, and to 94 healthcare organizations, which totaled Euro 872,551, excluding those related to R&D in both cases.
- The *EFPIA Code of Practice*, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to all the company's divisions.
- In addition to Europe, Grifols applies this policy of transparency to the United States in accordance with CMS (Centers for Medicare & Medicaid Services) Open Payments.
- All related information is public and available on the Grifols corporate website: [www.grifols.com](http://www.grifols.com)

### **Information Published in Accordance with the EFPIA Code of Practice**

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and

sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities, and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.

---

## MEDIA

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

## LEGAL DISCLAIMER

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of*

*the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*